CytomX Therapeutics, Inc. financial data

Symbol
CTMX on Nasdaq
Location
151 Oyster Point Blvd., Suite 400, South San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 7, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 164 % +39.3%
Debt-to-equity 340 %
Return On Equity 159 %
Return On Assets 36 % +523%
Operating Margin 30.6 % +539%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 165M shares +111%
Common Stock, Shares, Outstanding 80.1M shares +19%
Entity Public Float 94.4M USD -17.3%
Common Stock, Value, Issued 2K USD +100%
Weighted Average Number of Shares Outstanding, Basic 129M shares +52.1%
Weighted Average Number of Shares Outstanding, Diluted 129M shares +52.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 141M USD +18%
Revenue from Contract with Customer, Excluding Assessed Tax 141M USD +18%
Research and Development Expense 68.3M USD -17.7%
General and Administrative Expense 29.6M USD -3.77%
Operating Income (Loss) 43.1M USD +654%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 48.2M USD +220%
Income Tax Expense (Benefit) 249K USD -93.8%
Net Income (Loss) Attributable to Parent 48M USD +333%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 49M USD +13.4%
Cash, Cash Equivalents, and Short-term Investments 79.9M USD -48.1%
Accounts Receivable, after Allowance for Credit Loss, Current 1.87M USD -32.6%
Assets, Current 165M USD +15.1%
Property, Plant and Equipment, Net 1.95M USD -41.3%
Operating Lease, Right-of-Use Asset 5.95M USD -41.8%
Goodwill 949K USD 0%
Other Assets, Noncurrent 56K USD -26.3%
Assets 175M USD +9.95%
Accounts Payable, Current 227K USD -62.8%
Employee-related Liabilities, Current 4.54M USD -20.9%
Accrued Liabilities, Current 11.5M USD -15.5%
Contract with Customer, Liability, Current 22.1M USD -82.2%
Liabilities, Current 39.2M USD -72.5%
Contract with Customer, Liability, Noncurrent 10.2M USD -72.1%
Operating Lease, Liability, Noncurrent 1.44M USD -79.1%
Other Liabilities, Noncurrent 4.24M USD +6.21%
Liabilities 55.1M USD -71%
Accumulated Other Comprehensive Income (Loss), Net of Tax 33K USD
Retained Earnings (Accumulated Deficit) -668M USD +6.7%
Stockholders' Equity Attributable to Parent 120M USD
Liabilities and Equity 175M USD +9.95%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -21M USD +19.2%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 30.6M USD -31.8%
Common Stock, Shares Authorized 300M shares +100%
Common Stock, Shares, Issued 80.1M shares +19%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Deferred Tax Assets, Valuation Allowance 162M USD -7.61%
Deferred Tax Assets, Gross 164M USD -8.16%
Operating Lease, Liability 9.39M USD -32.8%
Payments to Acquire Property, Plant, and Equipment 119K USD +3.48%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 48M USD +335%
Lessee, Operating Lease, Liability, to be Paid 10.1M USD -35.5%
Property, Plant and Equipment, Gross 18.7M USD +0.28%
Operating Lease, Liability, Current 5.44M USD +12%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.39M USD -23.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 5.73M USD +2.82%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 731K USD -57.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 4.39M USD -23.4%
Deferred Tax Assets, Operating Loss Carryforwards 62.5M USD +10.2%
Unrecognized Tax Benefits 20M USD +3.18%
Additional Paid in Capital 788M USD +15.1%
Amortization of Intangible Assets 36K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 2.11M USD -37.3%